Cargando…
Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice
Acinetobacter baumannii is increasingly refractory to antibiotic treatment in healthcare settings. As is true of most human pathogens, the genetic path to antimicrobial resistance (AMR) and the role that the immune system plays in modulating AMR during disease are poorly understood. Here we reproduc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159950/ https://www.ncbi.nlm.nih.gov/pubmed/35618774 http://dx.doi.org/10.1038/s41564-022-01126-8 |
_version_ | 1784719170005368832 |
---|---|
author | Huo, Wenwen Busch, Lindsay M. Hernandez-Bird, Juan Hamami, Efrat Marshall, Christopher W. Geisinger, Edward Cooper, Vaughn S. van Opijnen, Tim Rosch, Jason W. Isberg, Ralph R. |
author_facet | Huo, Wenwen Busch, Lindsay M. Hernandez-Bird, Juan Hamami, Efrat Marshall, Christopher W. Geisinger, Edward Cooper, Vaughn S. van Opijnen, Tim Rosch, Jason W. Isberg, Ralph R. |
author_sort | Huo, Wenwen |
collection | PubMed |
description | Acinetobacter baumannii is increasingly refractory to antibiotic treatment in healthcare settings. As is true of most human pathogens, the genetic path to antimicrobial resistance (AMR) and the role that the immune system plays in modulating AMR during disease are poorly understood. Here we reproduced several routes to fluoroquinolone resistance, performing evolution experiments using sequential lung infections in mice that are replete with or depleted of neutrophils, providing two key insights into the evolution of drug resistance. First, neutropenic hosts acted as reservoirs for the accumulation of drug resistance during drug treatment. Selection for variants with altered drug sensitivity profiles arose readily in the absence of neutrophils, while immunocompetent animals restricted the appearance of these variants. Secondly, antibiotic treatment failure in the immunocompromised host was shown to occur without clinically defined resistance, an unexpected result that provides a model for how antibiotic failure occurs clinically in the absence of AMR. The genetic mechanism underlying both these results is initiated by mutations activating the drug egress pump regulator AdeL, which drives persistence in the presence of antibiotic. Therefore, antibiotic persistence mutations present a two-pronged risk during disease, causing drug treatment failure in the immunocompromised host while simultaneously increasing the emergence of high-level AMR. |
format | Online Article Text |
id | pubmed-9159950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-91599502022-06-03 Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice Huo, Wenwen Busch, Lindsay M. Hernandez-Bird, Juan Hamami, Efrat Marshall, Christopher W. Geisinger, Edward Cooper, Vaughn S. van Opijnen, Tim Rosch, Jason W. Isberg, Ralph R. Nat Microbiol Article Acinetobacter baumannii is increasingly refractory to antibiotic treatment in healthcare settings. As is true of most human pathogens, the genetic path to antimicrobial resistance (AMR) and the role that the immune system plays in modulating AMR during disease are poorly understood. Here we reproduced several routes to fluoroquinolone resistance, performing evolution experiments using sequential lung infections in mice that are replete with or depleted of neutrophils, providing two key insights into the evolution of drug resistance. First, neutropenic hosts acted as reservoirs for the accumulation of drug resistance during drug treatment. Selection for variants with altered drug sensitivity profiles arose readily in the absence of neutrophils, while immunocompetent animals restricted the appearance of these variants. Secondly, antibiotic treatment failure in the immunocompromised host was shown to occur without clinically defined resistance, an unexpected result that provides a model for how antibiotic failure occurs clinically in the absence of AMR. The genetic mechanism underlying both these results is initiated by mutations activating the drug egress pump regulator AdeL, which drives persistence in the presence of antibiotic. Therefore, antibiotic persistence mutations present a two-pronged risk during disease, causing drug treatment failure in the immunocompromised host while simultaneously increasing the emergence of high-level AMR. Nature Publishing Group UK 2022-05-26 2022 /pmc/articles/PMC9159950/ /pubmed/35618774 http://dx.doi.org/10.1038/s41564-022-01126-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Huo, Wenwen Busch, Lindsay M. Hernandez-Bird, Juan Hamami, Efrat Marshall, Christopher W. Geisinger, Edward Cooper, Vaughn S. van Opijnen, Tim Rosch, Jason W. Isberg, Ralph R. Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice |
title | Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice |
title_full | Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice |
title_fullStr | Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice |
title_full_unstemmed | Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice |
title_short | Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice |
title_sort | immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during acinetobacter baumannii pneumonia in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159950/ https://www.ncbi.nlm.nih.gov/pubmed/35618774 http://dx.doi.org/10.1038/s41564-022-01126-8 |
work_keys_str_mv | AT huowenwen immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT buschlindsaym immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT hernandezbirdjuan immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT hamamiefrat immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT marshallchristopherw immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT geisingeredward immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT coopervaughns immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT vanopijnentim immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT roschjasonw immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice AT isbergralphr immunosuppressionbroadensevolutionarypathwaystodrugresistanceandtreatmentfailureduringacinetobacterbaumanniipneumoniainmice |